Remove category agency-information
article thumbnail

Medicare Advantage RADV Audit Final Rule Challenged in Court

Healthcare Law Blog

The Centers for Medicare & Medicaid Services (“CMS”) released the final rule on risk adjustment data validation (“RADV”) audits of Medicare Advantage (“MA”) organizations (the “Final Rule”) on January 30, 2023. This bargain is codified in the statutory mandate of 42 U.S.C. 1395w-23(a)(1)(C)(i) “to ensure actuarial equivalence.”

article thumbnail

HHS Issues Proposed Rule to Provide Clarity on Rights of Conscience in Healthcare

Healthcare Law Blog

Medicaid and Medicare The Balanced Budget Act of 1997, Public Law 105–33, 111 Stat. The Medicaid and Medicare statutes also contain conscience provisions related to the performance of advanced directives, religious nonmedical healthcare providers and their patients.

ACA 105
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

FDA Oversight of AI Software Developed by Health Care Providers

Health Law Advisor

In the last couple of years, each Fall, FDA has been updating a list of machine learning applications in health care that the agency has cleared or otherwise approved. [1] Although that regulation was published in 2011, FDA still uses it as the foundation for determining whether an organization qualifies as an MDDS manufacturer.

FDA 98
article thumbnail

FDA and Off-Label Communication – Getting Closer to Truth

Drug & Device Law

552 (2011); Thompson v. The FDA’s chief concern about off-label communications from manufacturers has less to do with the safety of such uses − many of which are medical standard of care and Medicare reimbursable − than with the agency’s own bureaucratic imperative. E.g. , Sorrell v. IMS Health Inc. , Caronia , 703 F.3d

FDA 64
article thumbnail

Logical Contradiction Doctrine:  Buckman for Textualists

Drug & Device Law

280 (1995), decision that he joined in 1995 He joined a decision that found no preemption by virtue of a governmental decision not to regulate in Myrick and did not object to boilerplate description of obstacle preemption as an accepted preemption category Then in the 5-4 Geier v. Bartlett , 570 U.S. Levine , 555 U.S. citation in PLIVA, Inc.

FDA 72